Navigation Links
FDA Approves Combination Contraceptive Containing a Folate
Date:9/24/2010

SILVER SPRING, Md., Sept. 24 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Beyaz tablets, an estrogen/progestin combined oral contraceptive that also contains a folate (levomefolate calcium 0.451 mg).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Levomefolate calcium is a metabolite of folic acid, a water-soluble B-vitamin that helps produce and maintain new cells in the body. A known association of low folate levels and neural tube defects (e.g., spina bifida) has resulted in recommendations that women of childbearing age supplement their diet with folate.

Beyaz is based on the approved product YAZ, which contains the same doses of estrogen and progestin, and is approved for:

  • Prevention of pregnancy
  • Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive for contraception and
  • Treatment of moderate acne vulgaris in women at least 14 years of age, only if the patient desires an oral contraceptive for birth control.

In addition to the approved YAZ indications, Beyaz also is approved for the secondary indication in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.

The primary efficacy study for Beyaz was a multicenter, double-blind, randomized, controlled U.S. trial in 379 healthy women age 18 to 40 who were treated with Beyaz or YAZ alone for up to 24 weeks. Beyaz was found to increase folate levels in women. In a German study of Beyaz, folate levels remained elevated for several weeks following discontinuation of Beyaz.  Safety and efficacy data for contraception, PMDD, and acne indications were obtained from previous YAZ clinical trials.

The most common side effects reported by users of combined oral contraceptives are irregular uterine bleeding, nausea, breast tenderness, and headaches. Other serious side effects include vascular events (blood clots) and liver disease.  Women over age 35 who smoke should not use this product as cigarette smoking increases further the risk of serious cardiovascular events.  The common adverse events for Beyaz are expected to be the same as those for YAZ.  There were no findings from the clinical trials with Beyaz to suggest a change in the overall safety profile compared to that of YAZ.

Beyaz is manufactured by Bayer HealthCare Pharmaceuticals Inc., the U.S.-based business arm of Bayer HealthCare LLC, a subsidiary of Bayer AG.

Approved Drugs: Questions and Answers http://www.fda.gov/Drugs/ResourcesForYou/Consumers/UCM054420

Contact: Elaine Gansz Bobo, 301-796-7567, elaine.bobo@fda.hhs.gov


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
2. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
3. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
4. FDA Approves Pediatric Use of Chemical Poisoning Treatment
5. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
6. FDA Approves Vaccines for the 2010-2011 Influenza Season
7. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
8. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
9. U.S. FDA Approves Improved Performance of Riverain Medicals OnGuard Chest X-ray Computer-Aided Detection Technology
10. FDA Approves New Injectable Osteoporosis Treatment for Postmenopausal Women
11. FDA Approves New Treatment for Late-Onset Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know ... nor would a pharmacist using that same scale to dispense medication. The first example ... , These illustrations show why it is important to have the right balance for ...
(Date:7/24/2017)... BEACH, Calif. (PRWEB) , ... July 24, 2017 , ... ... ranging from food addiction to sexual abuse, and how she has overcome them. “Forbidden ... traumatic instances in her life and how she has risen above. , In “Memories,” ...
(Date:7/24/2017)... ... July 24, 2017 , ... Right ... future. , The agency is hammering out a game plan to implement changes ... laws ever to affect FDA-regulated firms. The new law:, , ...
(Date:7/24/2017)... ... July 24, 2017 , ... “A Short Walk to the Mailbox”: a ... the creation of published author, Ed Clark. Ed Clark is a church music ... churches as a minister of music and worship leader for over fifty years. ...
(Date:7/23/2017)... , ... July 23, 2017 , ... A 20-year-long ... St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports ... the disease offers very few benefits. , In the cases involved with this ...
Breaking Medicine News(10 mins):